Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 ...
MedPage Today on MSN
Better Survival in Refractory CRC With Chemo Plus Bevacizumab, Real-World Study Says
OS of 8.9 months versus 5.8 months with trifluridine/tipiracil alone, supporting phase III ...
Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of ...
New presentations for tildrakizumab-asmn explore real-world use in U.S. patients using Medicare New data specific to patients with skin of color expands ...
Background Patients with heart failure (HF) frequently suffer from undetected declines in cardiorespiratory fitness (CRF), which significantly increases their risk of poor outcomes. However, current ...
Genetix delivers strong 2025 revenue growth resulting in the Company’s first ever profitable quarterIn 2025, >100 U.S. patients were treated and >150 U.S. patients completed their first cell ...
Orsini, a leader in rare disease pharmacy solutions, has been selected by Genetix Biotherapeutics Inc. as a specialty pharmacy partner for three FDA-approved autologous hematopoietic stem cell-based ...
Clinicians should treat ventilator‑associated pneumonia (VAP) until the infection is controlled and the patient is clearly ...
Excerpted with permission from the publisher The Emperor of All Maladies: A Biography of Cancer (Revised Edition, 2026), Siddhartha Mukherjee, published by Fourth Estate, HarperCollins India.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results